2021 Annual Report cover

IBRI 2021 Annual Report “Accelerating Biomedical Innovation”

read the report

Timothy Richardson, PhD

Scientific Director of Molecular Innovation

Joined the IBRI in February 2021

Timothy Richardson

Timothy Richardson, PhD, is a senior research professor in the department of clinical pharmacology at the Indiana University (IU) School of Medicine where his primary responsibilities include leading the Medicinal Chemistry Core of the IUSM-Purdue TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer's Disease) Center.

Prior to his transition to the IU School of Medicine, he was a research fellow at Eli Lilly and Company. During his industrial career, he contributed to discovery programs that delivered new molecular entities for the treatment of endocrine, musculoskeletal and autoimmune diseases. He led technology platform teams focused on gene regulation, epigenetics, and nuclear receptors. He also served as a group leader in discovery chemistry, a role in which he guided multiple discovery teams that built a portfolio of small molecule therapeutics for the treatment of autoimmune diseases. Richardson finished his career at Eli Lilly and Company as a founding member of the RNA therapeutics team focused on oligonucleotide-based medicines.

In his role at the Indiana Biosciences Research Institute, he is applying his academic and industrial experience in collaboration with institute scientists and external research partners to drive translational science that rapidly advances novel therapeutics for unmet medical needs.

View Richardson's published research here.

Areas of Expertise

  • Drug discovery and development
  • Medicinal chemistry
  • Pharmacology

Education

  • Doctor of Philosophy (Organic Synthesis), University of Minnesota, 1997
  • Bachelor of Science (Biochemistry), University of Minnesota, 1993

Awards & Certifications

  • NIH NCATS ASPIRE Reduction-to-Practice Challenge, 2020

Honorary Societies

  • Phi Beta Kappa